Analyzing Regenxbio’s Valuation Metrics
Regenxbio (RGNX) generated revenues, chiefly from licensing, of $40.03 million in the second quarter compared to $6.56 million in Q2 2017. For fiscal 2018, Regenxbio is expected to generate revenues of $194.55 million compared to $10.39 million in fiscal 2017. The increase in revenues helped Regenxbio generate a net income of $10.59 million in the second quarter compared to a net loss of $14.47 million in the second quarter of 2017.